# Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

> **NCT04008706** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 552 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04008706
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-17
- **Primary completion:** 2025-11-04
- **Final completion:** 2025-11-04
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2025-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008706, "Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04008706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*